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Abstract
Background: Smoking and stress, pancreatic cancer (PanCa) risk factors, stimulate nitrosamine 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and catecholamines production respectively. NNK and
catecholamine bind the b-adrenoceptors and induce PanCa cell proliferation; and we have previously suggested
that b-adrenergic antagonists may suppress proliferation and invasion and stimulate apoptosis in PanCa. To clarify
the mechanism of apoptosis induced by b2-adrenergic antagonist, we hypothesize that blockage of the b2-
adrenoceptor could induce G1/S phase arrest and apoptosis and Ras may be a key player in PanCa cells.
Results: The b1 and b2-adrenoceptor proteins were detected on the cell surface of PanCa cells from pancreatic
carcinoma specimen samples by immunohistochemistry. The b2-adrenergic antagonist ICI118,551 significantly
induced G1/S phase arrest and apoptosis compared with the b1-adrenergic antagonist metoprolol, which was
determined by the flow cytometry assay. b2-adrenergic antagonist therapy significantly suppressed the expression
of extracellular signal-regulated kinase, Akt, Bcl-2, cyclin D1, and cyclin E and induced the activation of caspase-3,
caspase-9 and Bax by Western blotting. Additionally, the b2-adrenergic antagonist reduced the activation of NFB
in vitro cultured PanCa cells.
Conclusions: The blockage of b2-adrenoceptor markedly induced PanCa cells to arrest at G1/S phase and
consequently resulted in cell death, which is possibly due to that the blockage of b2-adrenoceptor inhibited NFB,
extracellular signal-regulated kinase, and Akt pathways. Therefore, their upstream molecule Ras may be a key factor
in the b2-adrenoceptor antagonist induced G1/S phase arrest and apoptosis in PanCa cells. The new pathway
discovered in this study may provide an effective therapeutic strategy for PanCa.
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Introduction
Pancreatic cancer (PanCa) remains a lethal disease [1].
There is increasing evidence suggesting that many fac-
tors such as smoking, stress, chronic depression and a
high-fat diet, with cardiovascular disease and stress
patients may contribute to PanCa genesis and develop-
ment but the underlying mechanisms are not clear
[2-4]. Previous studies indicate that the enhanced
tumour progression by smoking-stimulated nitrosamine
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
production and stress-stimulated autonomic activation
of nervous system [5,6]. The autonomic activation of
nerve system results in the release of catecholamines
from the adrenal gland and sympathetic nerve terminals.
Further studies suggest that both NNK and constantly
high level of catecholamines modulate the activity of
multiple components of the tumour microenvironment
and consequently promote tumour-cell growth via b-
adrenoceptors [4,7-9].
b-adrenoceptors are members of the superfamily of G
protein-coupled adrenergic receptors, which mediate
actions of the endogenous catecholamines in a variety of
target cells [10,11]. b1-a n db2-adrenoceptors have been
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and Panc-1 cell lines [12-14]. NNK functions as a b-
adrenergic agonist and it has been shown that the
binding of NNK or catecholamines to the b-adreno-
ceptors induce PanCa cell proliferation by activating
the cyclic adenosine monophosphate (cAMP)/protein
kinase A (PKA) pathways in PanCa cells [15]. The con-
sequence of PKA signalling leads to the transcriptional
activation of proteins involved in proliferation via
cAMP response element binding protein (CREB), acti-
vator protein 1 (AP-1) or NF-B [15-17]. Recent
reports have shown that the agonists of the b2-adreno-
ceptor stimulate the activation of Ras and Src tyrosine
kinases via the mitogen-activated protein kinase
(MAPK) pathway in cancer cells and fibroblasts
[18-20]. Ras activates several signalling pathways that
lead to transcriptional activation of genes related to
cell proliferation and antiapoptotic signalling cascades,
including the Raf/MEK/extracellular signal-regulated
kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)/
ATP-dependent tyrosine kinases (Akt)/Phosphatase
and tensin homolog deleted on chromosome 10
(PTEN) pathways and NF-B [17,21].
Previous studies suggested that b-adrenergic antago-
nists may suppress cell proliferation and invasion and
induce apoptosis in PanCa [14,22], and also b2-adrener-
gic agonist can stimulate the production of cAMP and
activation of G-protein effectors Gs [23]. However, the
mechanism of PanCa cell death induced by b2-adrener-
gic antagonist is not clear. In this study, we determined
the effects of b2-adrenergic antagonist ICI118,551 on
PanCa tumor growth and the underlying mechanism in
vitro and in vivo.
Materials and methods
Tumor tissues, Cell lines and cell culture
Forty-eight pancreatic carcinoma specimens were
obtained from the Department of Hepatobiliary and
Pancreas Surgery, the First Affiliated Hospital of Xi’an
Jiaotong University. The protocol was approved by The
Human Research Review Committee at the University
Hospital. The human ductal pancreatic adenocarcinoma
cell lines, MIA PaCa-2 and the BxPC-3 were purchased
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). The MIA PaCa-2 cell line har-
bours an activating point mutation in codon 12 of the
k-ras gene, whereas BxPC-3 does not have that k-ras
mutation [24]. The cells were cultured in DMEM
(Gibco, Grand Island, NY, USA) with 10% (v/v) heat-
inactivated FBS (Gibco, Grand Island, NY, USA), peni-
cillin (100 U/ml) and streptomycin (100 mg/ml)at 37°C
with 5% CO2 and 95% relative humidity. Before each
experiment, cells were seeded at a density of 5 × 10
4
cells/cm
2.
Immunohistochemistry staining
Immunohistochemical staining for b1-adrenoceptor and
b2-adrenoceptor were performed using the SABC kit
according to the manufacturer’s instruction (Abfrontier,
Korea). The sections were incubated with primary anti-
bodies (Abcam, Cambridge, MA, USA) overnight at 4°C
and then incubated with the appropriate biotinylated
secondary antibody (Abcam, Cambridge, MA, USA) for
30 min at room temperature. Sections were then incu-
bated with avidin/biotin complexes for 30 min at room
temperature. Following washing in PBS, immunoreactiv-
ity was visualized by using DAB reaction followed by
hematoxylin counter staining. For evaluation of protein
expression, the staining intensity was graded as 0 (nega-
tive), 1 (weak), 2 (medium) or 3 (strong). The slides
were graded by two investigators. The densitometry ana-
lysis of immunohistochemical staining was performed
using the Image-Pro Plus 4.5 software.
Cell cycle analysis
The cells after treatment were stained with propidium
iodide (PI) and then analysed using flow cytometry for
cell cycle according to the manufacturer’sp r o t o c o l .
After stimulation for 24 h with ICI118,551 (100 μM)
[13,14,25] (Sigma Chemical, St. Louis, MO, USA), MIA
PaCa-2 and BxPC-3 cells were fixed in ice-cold 70%
ethanol at 4°C. On the day of analysis, the cells were
then centrifuged (400 × g for 5 min) and washed once
in staining buffer. After centrifugation, the cells were
resuspended in 100 μL of staining buffer. The cells were
then treated with RNase A and incubated for 30 min at
37°C. After RNase A digestion, the cells were stained for
30 min at room temperature (protected from light) with
10 μg of PI in a final volume of 0.5 mL of staining buf-
fer. The samples were then analysed by flow cytometry.
The percentages of cells in G0-G1, S, and G2-M were
calculated using the ModFit computer program.
Animal studies and subrenal capsular assay
BALB/c athymic nude mice, 4 to 6 weeks old (Shanghai
Experimental Animal Center (Chinese Academy of
Sciences, China) were used for the subrenal capsule
assay. PanCa xenografts were generated by implantation
of MIA PaCa-2 and BxPC-3 cells into one flank of athy-
mic nude mice. Each group contains n ≥ 8 male athymic
nude mice (10 mice each group). On the day of the
experiment, mice were anesthetized, and the left kidney
was exposed. The same number of cells (1 × 10
8)i n2 5
μl was then injected into each mouse under the left
renal capsule. After three days, a 5 mg/kg/dose of
ICI118,551 was intraperitoneally injected into the mice
every day. After inoculation with the tumor cells, mice
were observed and sacrificed on day ten, when their left
kidneys were excised. The left renal capsule were fixed
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fin. Sections were cut on a microtome and mounted on
glass slides. For histopathology, routine H&E staining
was carried out. Animal care and experiments were car-
ried out in accordance with the guidelines of the Xi’an
Jiaotong University.
Electron microscopy
To evaluate the morphological features of cell death, the
cells in the control group or cells treated with or with-
out ICI118,551 (100 μM) were processed for transmis-
sion electron microscopy (TEM). Briefly, cells were
pelleted by centrifugation and fixed with 2.5% glutaral-
dehyde in 0.1 M cacodylate buffer, pH 7.4 for 1 h at 4°
C. After rinsing with cacodylate buffer, the specimens
were fixed in 1% cacodylate-buffered osmium tetroxide
for 2 h at room temperature, dehydrated in a graded
series of ethanol, briefly transferred to propylene oxide
and embedded in Epon-Araldite. Ultrathin sections (60-
80 nm thick) were cut with a diamond knife, placed on
formvar-carbon coated copper grids (200 mesh), stained
with uranyl acetate and lead citrate and observed with a
Jeol 100 SX TEM.
Determination of cell apoptosis by hoechst 33342
fluorescent staining
The cell death was assessed using Hoechst staining.
Briefly, cells were seeded in 24-well plates at 5 × 10
4
cells/well and treated with ICI118,551 (100 μM) for 24
h. After treatment, cells were stained with 10 μg/ml
Hoechst 33342 dye (Sigma Chemical, St. Louis, MO,
USA). Fixed cells were incubated overnight at 4°C and
visualized under a 365 nm UV light microscope. Quanti-
tative analysis was performed by counting the blue
fluorescent (apoptosis positive) cells from three indepen-
dent fields at 400× magnification. Values were expressed
as the percentage of apoptotic cells relative to the total
number of cells per field.
Analysis of the apoptosis rate by Annexin V-FITC/PI
The apoptosis rate was measured using Annexin V-
FITC/PI double staining followed by flow cytometry
(FCM) according to the instructions (BD Biosciences,
San Jose, CA, USA). After treatment with metoprolol
(25-200 μM) and ICI118,551 (25-200 μM) for 24 h,
MIA PaCa-2 and BxPC-3 cells were washed once with
ice-cold PBS and resuspended in binding buffer at a
concentration of 1 × 10
6 cells/ml. A total of 5 μLo f
Annexin V-FITC and 10 μLo f2 0m g / m LP Iw e r e
added to the cells, and the mixture was incubated for 15
min in the dark prior to the addition of 400 μlo fP B S .
Quantitative analysis of the apoptotic level was per-
formed using a flow cytometer (BD Biosystems, CA,
USA).
Electrophoretic mobility shift assays (EMSA)
The activity of NF-B in PanCa cells was determined
using An EMSA. Binding reaction mixtures (20 μl) con-
taining 3 μl of nuclear extract protein (2-5 μg/μl), 1 μl
of poly (dI-dC) in 10 mM Tris and 1 mM EDTA (1 μg/
μl), 1 μlo fM g C l 2 (100 mM), 2 μl of 25 mM DTT/2.5%
Tween-20, 1 μl of 1% NP-40, 2 μlo f1 0×B i n d i n gB u f -
f e r( 1 0 0m MT r i s ,5 0 0m MK C l ,1 0m MD T T ,p H7 . 5 ) ,
1 μlo fI R D y e ™ end labelled oligo probe (50 nM) (LI-
COR Biosciences, Lincoln, NE, USA) and 9 μlo fU l t r a
Pure water were incubated for 30 minutes at room tem-
perature. Proteins were separated by electrophoresis in a
native 5% polyacrylamide gel at 4°C in running buffer
(12.5 mM Tris borate, 0.25 mM EDTA; pH 8.0), then
imaged using the LI-COR Bioscience Odyssey Imaging
System according to the manufacturer’si n s t r u c t i o n s .
The sequence of the NF-B-specific probe was 5’-AGT
TGA GGG GAC TTT CCC AGG C-3’.
Western blotting analysis
The MIA PaCa-2 and BxPC-3 cells were treated with
metoprolol (100 μM) and ICI118,551 (100 μM) for 24
h .T h ep r o t e i n sw e r et h e ne x t r a c t e df r o mt h et r e a t e d
cells. The supernatant was collected and the total
protein concentration was measured using the BCA
assay kit (Pierce, Rockford, IL, USA) according to the
manufacturer’s instructions. The total proteins were
used for Western blotting analysis using specific anti-
bodies against caspase-3, caspase-9, Bcl-2, Bax, cyclin
D1, cyclin E (Abcam, Cambridge, MA, USA), pERK,
ERK, pAkt, and Akt (Cell Signal Technology, Beverly,
MA, USA). Thirty μg of total protein each sample
was separated by 12% SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE), and the protein was electrically
transferred onto a nitrocellulose membrane (Milli-
pore, Bedford, MA, USA). The membrane was then
blocked with TBST (10 mM Tris-HCl, pH 7.4, 150
mM NaCl, 0.1% Tween-20) containing 5% w/v non-
fat dry milk and incubated with the primary antibody
in TBST at 4°C overnight. The membrane was washed
three times and was then incubated with the second-
ary antibody for 2 h at room temperature. After
washing three times for 10 min each with 15 ml of
TBST, signallings were visualised by enhanced chemi-
luminescence (Pierce, Rockford, IL, USA) associated
fluorography.
Statistical analysis
The data were analysed by one-way ANOVA, and by the
nonparametric Kruskal-Wallis test. The relationship
between b-AR expression and clinical-pathologic charac-
ter were analysed by Chi-square test. Values were
expressed as the mean ± SEM and the differences were
considered statistically significant at P < 0.05.
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Expression of b-adrenoceptors in PanCa cell lines and
clinical samples
Our previous study showed that b1-a n db2-adrenergic
receptors were expressed in PanCa cells by Real-time
RT-PCR and Western blotting [14]. In the current
study, we further determined the expression of b1-a n d
b2-adrenergic receptors in pancreatic carcinoma speci-
mens using immunohistochemical staining. As shown in
Figure 1, PanCa cells in biopsy specimens express
bothb1-AR and b2-AR on the membrane in a large
number of epithelial cells and the b-ARs are localized in
t h ep l a s m am e m b r a n eo fp a n c r e a t i cc a n c e rc e l l s ,a n d
the representative images are shown in Figure 1. The 48
pancreatic carcinoma specimen samples from 30 males
and 18 females include 18 poorly differentiated pancrea-
tic carcinoma samples, 23 moderately differentiated pan-
creatic carcinoma samples, and 7 well-differentiated
pancreatic carcinoma samples. The relationship between
b-AR expression and clinical-pathologic character is
showed in the Table 1.
Cell cycle analysis after b-adrenergic antagonist treatment
Our early published study showed the optimal concen-
trations of ICI118,551 and metoprolol for PanCa cell
inhibition [14]. In brief, MIA PaCa-2 and BxPC-3 cells
were treated with various concentrations from 25 to 200
μM of ICI118,551 and metoprolol for 24 h, the maximal
response was obtained with a range of 100 - 200 μM
ICI118,551 and metoprolol [14]. In this study, we used
100 μMo fb2-adrenoceptor antagonist to examine the
effect on the cell cycle phase distribution of MIA PaCa-
2 and BxPC-3 cells. Based on the data of cell cycle ana-
lysis, we found a prolonged and prominent delay in pro-
gression from G0-G1 phase after the cells treated with
b-adrenoceptor antagonists (Figure 2A) (G0-G1 phase:
Control < Metoprolol < ICI118,551, P <0 . 0 5 ) ,a
decrease at the S phase (S phase: Control > Metoprolol
> ICI118,551, P < 0.05). Moreover, sub-G1 apoptotic
compartment was also observed in MIA PaCa-2 and
BxPC-3 cells (sub-G1 apoptotic compartment: Control <
Metoprolol < ICI118,551, P < 0.05). The percentages of
G0-G1 phase increased, and the percentages of S phase
decreased significantly in the cells exposed to
ICI118,551 compared with metoprolol treatment groups
(P < 0.05). The effect of the ICI118,551 on G1/S phase
arrest was greater in BxPC-3 cells than in MIA PaCa-2
cells (P < 0.05), suggesting a lower sensitivity to b2-adre-
noceptor antagonist in the cells containing an activating
k-ras mutation (Figure 2A).
Subrenal capsular assay
In the subrenal capsular assay, PanCa cells maintained a
solid structure and 3-dimensional growth under the kid-
ney capsule. The implanted tumors could invade the
kidney parenchyma, as demonstrated by detection of the
tumor cells surrounding the renal glomeruli and tubules.
As shown in Figure 2B, the implanted tumors are char-
acterized by malignant growth in vivo, including fre-
quent mitosis, neovascularization and invasion into
normal tissues. H&E staining results showed that the
proliferation of PanCa cells was strongly suppressed in
the renal capsule xenografts in mice after ICI118,551
treatment, the range and the depth of invasion was
Figure 1 Expression levels of b1 and b2-adrenoceptor in the human ductal pancreatic adenocarcinoma cells. Two representative
immunohistochemical staining of PanCa cells presented from 48 pancreatic carcinoma specimen samples (expressions of b1-adrenergic receptor
[b and e], the expressions of b2-adrenergic receptor [a and d] and the negative control [c] in).
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Clinical and pathologic character b1-AR expression score b2-AR expression score
Pathology
Well-differentiated (7) 3.2 2.5
Moderately differentiated (23) 4.9 4.3
Poorly differentiated (18) 5.4 5.3
TNM stage
I phase (7) 1.6 1.5
II phase (9) 3.9 3.4
III phase (19) 5.5* 5.9*
IV phase (13) 7.8* 7.9*
* P < 0.05 Analysed by Chi-square test.
Figure 2 b-adrenoceptor antagonists regulate cell cycle distribution in vitro cultured PanCa cells and limited prevented tumour
progression in vivo. The cell cycle distribution of PanCa cells in response to b-adrenoceptor antagonists (A), MIA PaCa-2 and BxPC-3 cells were
untreated (control) or treated with b-adrenoceptor antagonists: 100 μM metoprolol and 100 μM ICI118,551 for 24 h. b-adrenoceptor antagonists
limited tumor development in BALB/c athymic nude mice (B), the black dashed line was used to label the tumor range. H&E staining statistical
graph of tumor range showed that the proliferation of PanCa cells was strongly suppressd in renal capsule xenografts after ICI118,551 treatment
compared to non-treated cells (P < 0.05). *P < 0.05 when compared with controls.
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(Figure 2B, P < 0.05).
Cell apoptosis analysis after b-adrenergic antagonist
treatment
To investigate the morphological features of cellular
death induced by b-adrenergic antagonists, MIA PaCa-2
and BxPC-3 cells were analysed by TEM (Figure 3A).
Untreated MIA PaCa-2 and BxPC-3 cells exhibited typi-
cal ultrastructure that was characterised by a well-pre-
served plasma membrane, a nucleus with finely granular
and uniformly dispersed chromatin, and a cytoplasm
containing randomly distributed organelles and elec-
tron-dense granules (a and c). When cells were exposed
to ICI118,551 for 24 h, unequivocal signs of apoptosis
were detected. The morphological changes observed in
these cells included a progressive margination and con-
densation of the chromatin abutting the inner nuclear
envelope, nuclear fragmentation and cytoplasm shrink-
age (b and d).
In this study, the effect of ICI118,551 was examined in
PanCa cells by Hoechst staining (Figure 3A). Figure 3A
shows the characteristic appearance of the apoptotic
PanCa cells after treatment with ICI118,551 for 24 h.
The ICI118,551 treatment resulted in a significant
increase in the number of apoptotic cells (f and h in
Figure 3A), compared with basal apoptosis levels in
untreated controls (e and g in Figure 3A). The percen-
tage of apoptotic cells in the ICI118,551-treated group
was statistically different from the untreated control
cells (P < 0.05).
The percentages of early apoptotic cells increased sig-
nificantly after treatment with metoprolol (100 μM) and
ICI118,551 (100 μM) in MIA PaCa-2 and BxPC-3 cells
(Figure 3B). Additionally, exposure to the b2-adrenergic
antagonist ICI118,551 significantly increased cell
Figure 3 b-adrenoceptor antagonists induce PanCa cell death. The morphological features of cell death (necrosis and/or apoptosis) were
analyzed by using TEM (A [a-d]×5000). MIA PaCa-2 and BxPC-3 cell induced cell death by ICI118,551 (100 μM) was further confirmed by Hoechst
33342 fluorescent staining (A [e-h]×400), BxPC-3 cells were more sensitive to apoptosis induction than MIA PaCa-2 cells (P < 0.05). The apoptotic
MIA PaCa-2 and BxPC-3 cells were detected by flow cytometry (B). MIA PaCa-2 and BxPC-3 cells were treated with b-adrenoceptor antagonists
(100 μM). Exposure to the b2-adrenergic antagonist ICI118,551 significantly increased cell apoptosis compared to the metoprolol group (P <
0.05), BxPC-3 cells were more sensitive to apoptosis induction than MIA PaCa-2 cells(P < 0.05) (B). *P < 0.05 when compared with controls.
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b1-adrenergic antagonist metoprolol. BxPC-3 cells,
which contain the wild-type k-ras gene, were more sen-
sitive to apoptosis induction than MIA PaCa-2 cells,
which harbour an activation point mutation in codon 12
of the k-ras gene (P < 0.05).
Detection of ERK1/2 and Akt phosphorylation and NF-B
activation
We next investigated whether the effect of ICI118,551
on MIA PaCa-2 and BxPC-3 cells is associated with the
inhibition of NF-B activation and the induction of
ERK, and Akt dephosphorylation. The EMSA and WB
results showed that ICI118,551 completely suppressed
NF-B activation and significantly inhibited, ERK1/2
and Akt phosphorylation in MIA PaCa-2 and BxPC-3
cells after 24 h of treatment (Figure 4). We also found
that the b2-adrenergic antagonists inhibited NF-Ba c t i -
vation, ERK1/2 and Akt phosphorylation more signifi-
cantly than metoprolol in MIA PaCa-2 and BxPC-3 cells
(Figure 4).
The relationship of b-adrenoceptor antagonist treatment
with the expression of caspase-3, caspase-9, Bcl-2, Bax,
cyclin D1, and cyclin E
The caspase family proteases, caspase-3, caspase-9, Bcl-
2, and Bax, have been reported to be involved in apop-
tosis. In this current study, caspase-3, caspase-9, Bcl-2,
and Bax were detected by Western blotting in MIA
PaCa-2 and BxPC-3 cells after treatment with metopro-
lol (100 μM) and ICI118,551 (100 μM) for 24 h. As
shown in Figure 5, the cleavage of caspase-3, caspase-9,
and Bax increased after treatment with b-adrenergic
antagonists compared to the controls; ICI118,551
yielded more prominent bands than metoprolol. How-
ever, Bcl-2 decreased after treatment with b-adrenergic
antagonists. These results suggested that the b-adrener-
gic antagonists affect the expression levels of Bax, cas-
pase-3, and caspase-9 in MIA PaCa-2 and BxPC-3 cells.
We also examined the effects of ICI118,551 on the
regulatory proteins responsible for cell cycle progression.
The protein levels of cyclin D1 and cyclin E were
decreased in the two cell lines treated with b-adrenergic
antagonists. These results indicate that b2-adrenergic
antagonists have an effect on some of the cell cycle reg-
ulatory proteins responsible for the G1/S phase transi-
tion and on cell cycle progression (Figure 5).
Discussion
In this study, we have demonstrated that b-adrenocep-
tors are expressed in PanCa cells. Our data suggested
that the b-adrenergic antagonists were associated with
the inhibition of PanCa cell proliferation and the induc-
tion of apoptosis and G1/S phase arrest. In addition,
these effects mediated by the b2-adrenergic antagonist
were associated with the decreased expression of
pERK1/2, pAkt, and the activation of NF-B. Further-
m o r e ,w eh a v ef o u n dt h a tt h eb2-adrenergic antagonist
ICI118,551 significantly increased PanCa cell apoptosis
and G1/S phase arrest. The effects of ICI118,551 on the
rate of apoptosis and on G1/S phase arrest were stron-
ger than the b1-adrenoceptor antagonist metoprolol.
The G1/S phase transition is a particularly important
cell cycle control point. The cyclin D1 is a critical cell
Figure 4 b-adrenoceptor antagonists limited the activation of NF-B, ERK, and Akt. The NF-B activity in PanCa cells in response to b2-
adrenoceptor antagonists (A) and the phosphorylation state of ERK and Akt in PanCa cells in response to b2-adrenoceptor antagonists (B)* P <
0.05 when compared with controls.
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through G1 to S phase [17,26]. The growth stimulatory
signals in the form of increasing levels of cyclin D1 are
received by the cells in the early stage of G1,w h i c ha r e
then followed by increasing levels of cyclin E at the later
stage [26]. ICI118,551 could remarkably down-regulate
cyclin D1 and cyclin E expression, indicating that the
negatively regulatory effect of the ERK and Akt pathway
on the PanCa cell might be associated with the inhibition
of NF-B activation, a decrease in cyclin D1 expression
and a delay in the G1/S transition, and cell cycle process.
Our data has demonstrated that ICI118,551 could disen-
gage the prevention of apoptosis in PanCa cells via sup-
pression of the ERK and Akt pathways and NF-B
activation, and consequently limited the activation of Bax,
caspase-9, and caspase-3. The ERK and Akt pathway can
phosphorylate Bad, which allows Bcl-2 to form homodi-
mers that result in the generation of an antiapoptotic
response. This phosphorylation allows Bcl-2, Bcl-XL, and
Mcl-1 to bind Bax and prevent its activation [27-29].
The Ras pathway is commonly altered in PanCa. Acti-
vating point mutations in the K-ras gene are common
in ductal pancreatic carcinomas. NNK induces activating
point mutations in the ras gene, so it is conceivable that
the binding of NNK to b2- adrenoceptors may stimulate
this pathway via further activation of the Src tyrosine
kinase and Ras. The effects of the b2-adrenergic antago-
nist ICI118,551 on the G1/S phase arrest and apoptosis
are stronger in the BxPC-3 cells (expressing wild-type k-
ras) than in the MIA PaCa-2 cells containing a k-ras
mutation. Therefore, it suggests that k-ras may be a key
molecule involved in the blockage of the b-adrenoceptor
resulting in G1/S arrest and apoptosis in PanCa cells.
Previous study suggested that b2-adrenergic receptor
antagonist induces cell death by inhibiting the Ras/Raf/
Erk1/2 and PI3K/Akt pathways and mitochondrial death
pathway [30]. Our results demonstrated that b2-adrener-
gic receptor antagonist induced cell death in MIA PaCa-
2 and BxPC-3 cells is independent of the mitochondrial
Apaf-1/caspase-9 pathway.
Strategies to block b-adrenoceptors might be used to
prevent cancer in smokers and stress patients, and for the
prevention of cancer relapse and metastasis after conven-
tional chemotherapy or surgical resection [4,15]. Consider-
ing that the b2-adrenergic antagonists could be developed
as therapeutic and preventive agents, we suggest that
understanding the relationship between b2-adrenoceptor
signalling and G1/S phase arrest and apoptosis may pro-
vide a new strategic therapy for pancreatic cancer.
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